Press Release Archives | CereVasc | Neurological Disease Device Company

25 Sep, 2024

CereVasc Announces Journal of Molecular Therapy Publication Highlighting the eShunt® Platform as a CNS Gene Therapy Delivery Method

cerevasc2024-10-14T16:23:47+00:00September 25th, 2024|

17 Sep, 2024

CereVasc Announces Enrollment of the 50th Patient in Pilot Studies of the eShunt® System for Normal Pressure Hydrocephalus

cerevasc2024-10-14T16:19:05+00:00September 17th, 2024|

28 Aug, 2024

eShunt® System Receives FDA Breakthrough Device Designation

cerevasc2024-10-14T16:15:33+00:00August 28th, 2024|

16 Jul, 2024

CereVasc Announces Appointments of New Directors

Admin2024-07-18T18:46:24+00:00July 16th, 2024|

13 May, 2024

CereVasc Announces $70 Million Series B Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus

Admin2024-05-28T21:41:18+00:00May 13th, 2024|

07 May, 2024

CereVasc Receives FDA IDE Approval for the STRIDE Pivotal Study of the eShunt System for Treatment of Normal Pressure Hydrocephalus

cerevasc2024-05-28T21:43:24+00:00May 7th, 2024|

07 Feb, 2024

CereVasc’s eShunt® System to be Presented at the International Stroke Conference by Dr. Pedro Lylyk

cerevasc2024-05-10T14:17:27+00:00February 7th, 2024|

23 Jan, 2024

CereVasc’s eShunt® System Study Data Presented at the ABC WIN Seminar

cerevasc2024-10-14T16:28:16+00:00January 23rd, 2024|

03 Oct, 2023

CereVasc Announces 30th Patient Treated in Pilot Studies of the eShunt® System to treat Communicating Hydrocephalus

Admin2023-12-20T22:01:46+00:00October 3rd, 2023|

26 Sep, 2023

CereVasc eShunt® System Study Data Presented at Congress of Neurological Surgeons Meeting

Admin2023-11-06T22:49:34+00:00September 26th, 2023|